Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Eli Lilly shares are now positive for the year, up 10% since the start of January.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

The most popular injectable drugs are made by Eli Lilly, which sells its product as Zepbound for obesity and Mounjaro for diabetes, and Novo Nordisk, which sells its medicine as Wegovy for obesity ...

Investors should keep a close eye on Eli Lilly’s non-incretin portfolio performance, continued U.S. uptake of Zepbound and Mounjaro, and Eli Lilly's manufacturing capacity ahead of orforglipron ...

TOKYO -- U.S. drugmaker Eli Lilly has released its Zepbound obesity medication in Japan, targeting the millions said to suffer from the "hidden" scourge of buildups of visceral fat. "We believe ...

Ricks said in the press release. The big question is: will it be cheaper than Ozempic, Wegovy, Mounjaro, or Zepbound? While Eli Lilly has been tight-lipped about list price, analysts say there's a ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, Wegovy, Mounjaro and Zepbound, the pharmaceuticals giant said Thursday.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...